We aim to expand on the uses of TESA for T. cruzi infection by determining whether it can identify inter-strain variability to improve early diagnosis of Chagas disease and uptake of treatment.
a) Discuss the potential benefits of using TESA for T. cruzi infection.
b) Evaluate the significance of identifying inter-strain variability in Chagas disease.
c) Examine the role of early diagnosis in improving treatment outcomes.
d) Analyze the challenges associated with the uptake of treatment for Chagas disease.
